Pill vs. injection: new hope for acromegaly control

NCT ID NCT04837040

Summary

This study is testing if a daily pill called paltusotine can safely maintain control of acromegaly in people who are already stable on standard injectable treatments. About 58 adults will be randomly assigned to either keep taking the pill or switch to a placebo (inactive pill) for 36 weeks to see if the pill works. The main goal is to see if the pill keeps a key hormone (IGF-1) at a normal level and if it helps with symptoms like joint pain and fatigue.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACROMEGALY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Crinetics Study Site

    Los Angeles, California, 90048, United States

  • Crinetics Study Site

    Torrance, California, 90502, United States

  • Crinetics Study Site

    Baltimore, Maryland, 21205, United States

  • Crinetics Study Site

    Boston, Massachusetts, 02114, United States

  • Crinetics Study Site

    Philadelphia, Pennsylvania, 19104, United States

  • Crinetics Study Site

    Pittsburgh, Pennsylvania, 15212, United States

  • Crinetics Study Site

    Nashville, Tennessee, 37203, United States

  • Crinetics Study Site

    CABA, Buenos Aires, C1012AAR, Argentina

  • Crinetics Study Site

    Ciudad Autonoma de Buenos Aire, Buenos Aires, C1405BCH, Argentina

  • Crinetics Study Site

    Córdoba, X5000, Argentina

  • Crinetics Study Site

    Ghent, 9000, Belgium

  • Crinetics Study Site

    Fortaleza, Ceará, 60430-275, Brazil

  • Crinetics Study Site

    Curitiba, Paraná, 80030-110, Brazil

  • Crinetics Study Site

    Porto Alegre, Rio Grande do Sul, 90410-000, Brazil

  • Crinetics Study Site

    Rio de Janeiro, 20231-092, Brazil

  • Crinetics Study Site

    Rio de Janeiro, 21941-913, Brazil

  • Crinetics Study Site

    Sofia, 1431, Bulgaria

  • Crinetics Study Site

    Bron, 69677, France

  • Crinetics Study Site

    Pessac, 33604, France

  • Crinetics Study Site

    Budapest, 1083, Hungary

  • Crinetics Study Site

    Pécs, 7624, Hungary

  • Crinetics Study Site

    Beersheba, 8410101, Israel

  • Crinetics Study Site

    Petah Tikva, 4941480, Israel

  • Crinetics Study Site

    Roma, 00168, Italy

  • Crinetics Study Site

    San Isidro, Lima region, 15023, Peru

  • Crinetics Study Site

    Bydgoszcz, 85-605, Poland

  • Crinetics Study Site

    Poznan, 60-355, Poland

  • Crinetics Study Site

    Kemerovo, Kemerovo Oblast, 650066, Russia

  • Crinetics Study Site

    Novosibirsk, Novosibirsk Oblast, 630005, Russia

  • Crinetics Study Site

    Novosibirsk, Novosibirsk Oblast, 630087, Russia

  • Crinetics Study Site

    Samara, Samara Oblast, 443041, Russia

  • Crinetics Study Site

    Kazan', Tatarstan Republic, 420097, Russia

  • Crinetics Study Site

    Moscow, 117186, Russia

  • Crinetics Study Site

    Moscow, 119435, Russia

  • Crinetics Study Site

    Moscow, 125008, Russia

  • Crinetics Study Site

    Belgrade, 11000, Serbia

  • Crinetics Study Site

    Sheffield, South Yorkshire, S102JF, United Kingdom

  • Crinetics Study Site

    Coventry, West Midlands, CV2 2DX, United Kingdom

  • Crinetics Study Site

    London, W12 0HS, United Kingdom

Conditions

Explore the condition pages connected to this study.